多西环素在性传播感染管理中的应用
本文综述多西环素的药理学、疗效、安全性及耐药性,聚焦其在性传播感染管理中的重新应用。近十年多数国家细菌性性传播感染(梅毒、衣原体感染、淋病和生殖支原体感染)患病率上升,尤其在男男性行为者及合并HIV感染者中。鉴于部分性传播感染一线方案耐药增加及最新管理建议更新,多西环素因疗效、耐受性和口服给药成为有吸引力的选择,其预防指征亦在评估中。
要点
- 多西环素为廉价广谱抗菌药,脂溶性高、组织扩散好、生物利用度高、半衰期长,可每日口服一至两次。
- 近十年多数国家细菌性性传播感染患病率上升,主要见于男男性行为者,其中许多合并HIV感染。
- 部分性传播感染病原体对一线方案耐药增加,多西环素因疗效和耐受性成为有吸引力的替代选择。
核心结论
- 多西环素因疗效、良好耐受性和口服给药,在部分性传播感染治疗中较其他可用抗生素具吸引力。
- 多西环素在性传播感染预防中的指征已有评估。
研究设计与样本
- 本文为综述,旨在更新多西环素在性传播感染管理中的药理学、疗效、安全性和耐药性。
主要发现
- 多西环素为第二代四环素,全球已上市半个世纪,广泛用于多种细菌感染,尤其涉及胞内病原体,亦用于痤疮治疗或疟疾预防。
- 多西环素脂溶性使其在组织和器官中高扩散,生物利用度高,消除半衰期长,可每日口服一或两次。
- 近十年多数国家细菌性性传播感染(梅毒、衣原体感染、淋病和生殖支原体感染)患病率上升,主要见于男男性行为者,其中许多合并HIV感染。
临床怎么用
- 基于部分性传播感染一线方案耐药增加及最新管理建议,可考虑多西环素作为部分性传播感染的治疗选择。
- 多西环素在性传播感染预防中的指征已获评估,需关注其在该场景下的应用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Doxycycline is a second-generation tetracycline, available worldwide for half a century. It is an inexpensive broad-spectrum antimicrobial agent largely used in the management of several bacterial infections, particularly involving intracellular pathogens, as well as in the treatment of acne or for the prophylaxis of malaria. Physicochemical characteristics of doxycycline (liposolubility) allow a high diffusion in the tissues and organs. It has high bioavailability and a long elimination half-life allowing oral administration of one or two daily doses. Over the last decade, the prevalence of bacterial sexually transmitted infections (STIs) (syphilis, chlamydiosis, gonorrhoea and Mycoplasma genitalium infections) has increased in most countries, mainly in MSM, many of whom are infected with HIV. In light of increasing prevalence of resistance towards first-line regimens of some STI agents and recently updated recommendations for STI management, doxycycline appears to be an attractive option compared with other available antibiotics for the treatment of some STIs due to its efficacy, good tolerability and oral administration. More recently, indications for doxycycline in STI prophylaxis have been evaluated. Considering the renewed interest of doxycycline in STI management, this review aims to update the pharmacology of, efficacy of, safety of and resistance to doxycycline in this context of use.
引用
- Peyriere H, Makinson A, Marchandin H, et al. Doxycycline in the management of sexually transmitted infections. J Antimicrob Chemother. 2018. PMID: 29182717. doi:10.1093/jac/dkx420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。